AMACATHERA
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer, and other hard‑to‑reach target areas. AmacaThera is developing combination products at the interface of biomaterials and pharmaceuticals.
AMACATHERA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2016-04-26
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.amacathera.ca
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
16 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Maps Content Delivery Network HSTS ReCAPTCHA Organization Schema JsDelivr GStatic Google Static Content Pound Sterling
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners investment in Grant - AmacaThera
Paul Austin
Paul Austin investment in Series A - AmacaThera
Lumira Ventures
Lumira Ventures investment in Series A - AmacaThera
Inveready
Inveready investment in Series A - AmacaThera
StandUp Ventures
StandUp Ventures investment in Series A - AmacaThera
MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund investment in Series A - AmacaThera
BDC Capital’s Women in Technology Venture Fund
BDC Capital’s Women in Technology Venture Fund investment in Series A - AmacaThera
Johnson & Johnson Robotics and Digital Solutions
Johnson & Johnson Robotics and Digital Solutions investment in Grant - AmacaThera
BDC Capital’s Women in Technology Venture Fund
BDC Capital’s Women in Technology Venture Fund investment in Series A - AmacaThera
MBX Capital
MBX Capital investment in Series A - AmacaThera
Official Site Inspections
http://www.amacathera.ca Semrush global rank: 14.09 M Semrush visits lastest month: 60
- Host name: 104.21.96.1
- IP address: 104.21.96.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AmacaThera"
Amacathera | Transforming therapeutics to make a …
AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes …See details»
Dr. Mike Cooke | AmacaThera
Dr. Mike Cooke co-founded AmacaThera Inc. with Dr. Molly Shoichet in 2016 to commercialize novel hydrogels. Their lead product, AMT-143, is focused on improving postoperative pain …See details»
AmacaThera named CIX Top 20 Early company
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain …See details»
AmacaThera - Company Profile - innovationfactory.ca
AmacaThera is a clinical-stage biotechnology company developing a novel local drug delivery platform to improve patient outcomes across multiple therapeutic areas including post …See details»
AmacaThera - EAHN
AmacaThera’s lead product AMT-143 is a long-acting injectable therapeutic for post-operative pain management. The product is composed of a local anesthetic drug formulated in AmacaThera’s proprietary drug delivery biomaterial – …See details»
RBCx features AmacaThera’s journey
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey. Read the full AmacaThera profile on RBCx .com. The article includes interviews with …See details»
AmacaThera - Crunchbase Company Profile & Funding
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer, and other hard‑to‑reach …See details»
AmacaThera | Ontario at the Biotech Showcase 2025 | Source from …
AmacaThera is a venture-backed clinical stage biotechnology company supported by institutional investors including; Lumira Ventures, BDC Capital’s Women in Technology Venture Fund, …See details»
AmacaThera: Revolutionizing Pain Management | RBCx
Jun 12, 2024 Learn how AmacaThera’s innovative biotechnology is transforming pain relief, reducing opioid use, and improving patient treatment options.See details»
News & Media | AmacaThera
AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes …See details»
AmacaThera - LinkedIn
AmacaThera | 2,899 followers on LinkedIn. Transforming therapeutics to make a difference in patient health | At AmacaThera, we specialize in developing innovative drug delivery solutions …See details»
Paul Austin | AmacaThera
AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, …See details»
AmacaThera Announces Close of Oversubscribed Series A Financing
TORONTO, February 22, 2021 — AmacaThera Inc. announced today that it has completed an oversubscribed C$10.3 million Series A financing to support development of AMT-143, the …See details»
AmacaThera Announces Successful Phase 1 Results of First-in
Nov 26, 2024 AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, announced results from its …See details»
AmacaThera closes $4M in Series A to advance non-opioid …
Nov 27, 2023 AmacaGel and AMT-143 Leveraging the AmacaGel platform, AmacaThera is developing AMT-143 with the objective of it being a best-in-class, non-opioid, therapeutic able …See details»
AmacaThera Partners with Global Pharma to Develop Long-Acting …
Apr 22, 2025 AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, announced a new pipeline program in collaboration with a leading global pharmaceutical …See details»
Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive
TORONTO, Jan. 8, 2025 /CNW/ - AmacaThera, a leading clinical-stage biotechnology company revolutionizing long-acting therapies, announces the appointment of Dr. Eyal S. Ron to its …See details»
AmacaThera Closes Series A Extension to Advance Clinical
Nov 28, 2023 AmacaThera Inc., a resident company of Johnson & Johnson Innovation, JLABS @ Toronto is a clinical-stage company transforming therapeutics to make a difference in …See details»
CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly…
ICYMI: Thanks to CBC’s Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.See details»
AmacaThera Announces Phase 1 Results of First-in-Human Study …
TORONTO, Nov. 20, 2024 /CNW/ - AmacaThera today announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company's …See details»